Cardiotoxicity Assessment
Cardiotoxicity Assessment - Related Videos
04:47
Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity
0 Views •
2023
This video describes the technique of creating a zebrafish cardiomyopathy model with minimal variations among experimental groups and in the sample, we create zebrafish cardiomyopathy model using the drug doxorubicin.
11:00
Using Chicken Embryo as a Powerful Tool in Assessment of Developmental Cardiotoxicities
0 Views •
Cited by 2 •
2021
Chicken embryos, as a classical developmental model, are used in our lab to assess developmental cardiotoxicities following exposure to various environmental contaminants. Exposure methods and morphological/functional assessment methods established are described in this manuscript.
14:03
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
0 Views •
Cited by 6 •
2023
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer an alternative to using animals for preclinical cardiotoxicity screening. A limitation to the widespread adoption of hiPSC-CMs in preclinical toxicity screening is the immature, fetal-like phenotype of the cells. Presented here are protocols for robust and rapid maturation of hiPSC-CMs.
08:36
Neurotoxicity Assessment in Adult Danio rerio using a Battery of Behavioral Tests in a Single Tank
0 Views •
Cited by 3 •
2023
Here, we present a comprehensive behavioral test battery, including the novel tank, Shoaling, and social preference tests, to effectively determine the potential neurotoxic effects of chemicals (e.g., methamphetamine and glyphosate) on adult zebrafish using a single tank. This method is relevant to neurotoxicity and environmental research.
06:50
Systematic Assessment of Well-Being in Mice for Procedures Using General Anesthesia
0 Views •
Cited by 25 •
2018
We developed a protocol to assess well-being in mice during procedures using general anesthesia. A series of behavioral parameters indicating levels of well-being as well as glucocorticoid metabolites were analyzed. The protocol can serve as a general aid to estimate the degree of severity in a scientific, animal-centered manner.
FAQs
Each measurement addresses a different outcome. Cardiac biomarkers can indicate myocardial injury, electrocardiography can reveal abnormal electrical activity, and imaging can show changes in cardiac structure or function. Contractility testing focuses on the heart’s pumping performance. Using these complementary readouts helps distinguish tissue damage, electrical disturbances, and impaired contraction rather than relying on a single indicator.
Evaluating outcomes across doses helps determine whether cardiac effects become more pronounced as exposure increases. Repeating measurements over time can show whether injury, electrical abnormalities, or reduced pumping develops, persists, or changes after treatment. This information clarifies the relationship between treatment and cardiac effects, supporting decisions about hazard identification and appropriate monitoring.
A control comparison provides a reference for interpreting changes observed after treatment. Investigators can examine whether biomarker levels, electrical activity, imaging findings, or contractility differ from untreated or comparison groups. When these differences are also assessed over time, the analysis can better separate treatment-associated cardiac effects from the underlying measurements seen without exposure.
A typical workflow begins by selecting cardiac outcomes relevant to the treatment, then measuring biomarkers, electrical activity, cardiac function, or contractility in treated and comparison groups. Investigators repeat or compare measurements over time and examine dose-related patterns where appropriate. Integrating these results provides a broader assessment of possible injury, arrhythmia risk, or impaired pumping.
Researchers use these evaluations to identify hazardous compounds and characterize cardiac effects before or during medical research. Findings can reveal whether a treatment is associated with myocardial injury, abnormal electrical activity, or reduced pumping function. The results support safer drug development by helping teams recognize risks and determine where clinical monitoring may be needed.
Cardiac safety findings help clinicians and researchers balance a therapy’s potential benefit against risks such as arrhythmia, heart failure, or myocardial injury. Biomarker, electrocardiographic, imaging, and contractility results can inform monitoring strategies and highlight changes that require attention. This is especially relevant when an effective treatment may also produce clinically important cardiac effects.